Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 1:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Myocardial Infarction
Interventions: Stress Challenge; Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Clostridium Difficile Infection
Interventions: Cadazolid, Vancomycin capsule, Vancomycin solution; Drug
Lead sponsor: Actelion; Industry
Eligibility: Up to 18 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Idaho Falls, Idaho • Chicago, Illinois • Shreveport, Louisiana + 2 more

Conditions: Lung Inflammation, HIV Seropositivity
Interventions: ECIGS, mobile contingency management (mCM), Usual brand; Other · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Asthma
Interventions: Fluticasone Propionate, Water Mouthwash, EVOOW Mouthwash; Drug · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: End Stage Renal Disease (ESRD), Kidney Disease
Interventions: Performance Feedback Reports on Referral and Evaluation Closures, Dialysis Facility Awareness Campaign, Patient Contact via Preferred Method, Phone Call to Dialysis Facility During the Patient's Dialysis Session, Phone Call to Provider, Transplant Referral Communication Platforms or Email to Communicate Patient Status and No-Show, Audit and Tracking of Patient Contact Attempts Prior to Referral Closure; Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 14,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Atlanta, Georgia • Indianapolis, Indiana • Durham, North Carolina + 1 more

Conditions: Obesity
Interventions: Small change approach to improve physical activity and diet, MOVE! Usual Care; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Cleveland, Ohio

Conditions: Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms, Vulvar Diseases
Interventions: E7 TCR cells, Aldesleukin, Fludarabine, Cyclophosphamide, EKG, Biopsy, Chest CT and MRI or PET, PFT, Granisetron, Ondansetron, Droperidol, Prochlorperazine, Diphenoxylate HCL, Atropine sulfate, Codeine sulfate, Loperamide, Indomethacin, Acetaminophen, Diphenhydramine HCL, Hydroxyzine HCL, Meperidine; Biological · Drug · Diagnostic Test + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 2
States / cities: Bethesda, Maryland • New Brunswick, New Jersey

Conditions: Arthritis, Osteo Arthritis Knee and Hip
Interventions: OACareTools+; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 99 Years
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Recurrent Glioblastoma Multiforme(GBM)
Interventions: ACT001, ACT001 + Pembrolizumab; Drug
Lead sponsor: Accendatech USA Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Osteoarthritis, Rheumatoid Arthritis, Post-traumatic Arthritis, Ununited Humeral Head Fracture, Irreducible 3-and 4-part Proximal Humeral Fractures, Avascular Necrosis, Gross Rotator Cuff Deficiency, Revision Total Shoulder Arthroplasty
Interventions: Trabecular Metal Reverse Shoulder System; Device
Lead sponsor: Zimmer Biomet; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 4
States / cities: San Francisco, California • Louisville, Kentucky • Egg Harbor, New Jersey + 1 more

Conditions: Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Interventions: Blinatumomab, Low-intensity chemotherapy regimen, SOC chemotherapy regimen; Drug
Lead sponsor: Amgen; Industry
Eligibility: 40 Years to 100 Years
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 7
States / cities: Duarte, California • Orange, California • San Francisco, California + 4 more

Conditions: Colorectal Cancer
Interventions: FOLFIRI, E7820, Bevacizumab; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: Denver, Colorado • Berkeley Heights, New Jersey • Mount Holly, New Jersey + 3 more

Conditions: Breast Cancer, Cancer of the Breast
Interventions: LS301, Cancer Vision Goggles and standard fluorescence imaging systems, Surgery; Drug · Device · Procedure
Lead sponsor: Samuel Achilefu; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Generalized Anxiety Disorder
Interventions: Cognitive Behavioral Therapy, Venlafaxine XR; Behavioral · Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostatic Neoplasms
Interventions: JNJ-78278343, JNJ-87189401, Apalutamide, Lutetium Lu-177 Vipivotide Tetraxetan, JNJ-101556143; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 13
States / cities: Aurora, Colorado • Atlanta, Georgia • Minneapolis, Minnesota + 10 more

Conditions: Major Depressive Disorder
Interventions: Behavioral Activation, Exercise Intervention, Stretching Intervention; Behavioral
Lead sponsor: Boston University Charles River Campus; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Breast Cancer, Solid Tumors
Interventions: Alisertib, MLN0128; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 101 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma
Interventions: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Doxorubicin Hydrochloride, Ibrutinib, Laboratory Biomarker Analysis, Methotrexate, Rituximab, Vincristine, Vincristine Sulfate; Drug · Other · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ocular Inflammation and Pain After Cataract Surgery
Interventions: APP13007, 0.05%, APP13007, 0.1%, APP13007 Placebo, 0.05%, APP13007 Placebo, 0.1%; Drug
Lead sponsor: Formosa Pharmaceuticals, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Phoenix, Arizona • Inglewood, California • Rancho Cordova, California + 5 more

Conditions: Acute Myocardial Infarction
Interventions: Educational Tool; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Anemia
Interventions: LY2787106, Iron Supplementation; Drug · Dietary Supplement
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 9
States / cities: La Jolla, California • Santa Monica, California • Indianapolis, Indiana + 6 more

Conditions: Rectal Cancer, Colorectal Cancer
Interventions: Photoacoustic imaging, photoacoustic microscopy, Endorectal photoacoustic imaging probe, Reader Performance; Device · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 19 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Skin Aging
Interventions: Investigational Facial Serum #3, Investigational Facial Serum #1, Investigational Facial Serum #2; Other
Lead sponsor: Victoria Collotta; Industry
Eligibility: 35 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Needham, Massachusetts

Conditions: PSMA PET-Positive Castration-Resistant Prostate Cancer
Interventions: In-111 rosopatamab tetraxetan, 45 kBq/kg Ac-225 rosopatamab tetraxetan, 45 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan, 60 kBq/kg Ac-225 rosopatamab tetraxetan, Single dose 22 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan, Single dose 34 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan, Single dose 45 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan, 55 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan, 60 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan; Biological
Lead sponsor: Convergent Therapeutics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 9
States / cities: San Diego, California • Boston, Massachusetts • St Louis, Missouri + 4 more

Search by objective public record fields.

Mental Stress and Myocardial Ischemia After MI: Sex Differences, Mechanisms and Prognosis

Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD)

Effects of E-cigarettes (ECIGs) on Pulmonary Inflammation and Behavior in HIV Infected Smokers

Novel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate

RaDIANT Health Systems Intervention

Coaching Veterans to Healthy Weights and Wellness

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

Osteoarthritis Care Tools for Primary Care Providers in Family Medicine and Geriatrics Clinics

A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme

Outcomes Study of the Trabecular Metal (TM) Reverse Shoulder System

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer

Real-time Intraoperative Breast Cancer Visualization for Margin Assessment

Combined Treatment for Generalized Anxiety Disorder (GAD)

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

Efficacy of Adjunctive Exercise for the Behavioral Treatment of Major Depression

Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery

PLATFORM to Maximize Patient Knowledge of Health Goals After Acute Myocardial Infarction

A Phase 1 Study of LY2787106 in Cancer and Anemia

Ultrasound and Photoacoustic Imaging for Enhanced Differential Diagnosis of Rectal Cancer

A Clinical Study to Evaluate the Efficacy of Activated Silk™ 27P-α in Subjects, Aged 35-65 Years of Age, to Improve the Signs of Aging, by Comparing to a Placebo

Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)